Extended Data Fig. 1: Key trial eligibility criteria, randomization scheme, and schedule of key study activities. | Nature Medicine

Extended Data Fig. 1: Key trial eligibility criteria, randomization scheme, and schedule of key study activities.

From: A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial

Extended Data Fig. 1

Eligible patients were randomized to receive 30 mg rentosertib QD, 30 mg rentosertib BID, 60 mg rentosertib QD, or placebo administered over 12 weeks with periodic assessment and plasma sampling. IPF, idiopathic pulmonary fibrosis; FVC, forced vital capacity; FEV1, forced expiratory volume in one second; DLCO, diffusion capacity of the lung for carbon monoxide; SOC, standard-of-care; QD, once-daily; BID, twice-daily; HRCT, high-resolution computed tomography; 6MWD, six-minute walk distance; LCQ, Leicester cough questionnaire; PK, pharmacokinetics; EOT, end-of-trial; EOS, end-of-study.

Back to article page